Dr. Cusnir on the Role of Ramucirumab in Gastric Cancer

Video

Mike Cusnir, MD, discusses the utilization of ramucirumab in gastric cancer.

Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utilization of ramucirumab (Cyramza) in gastric cancer.

Ramucirumab, according to Cusnir, is one of the more interesting agents in gastric cancer due to an antiangiogenic agent being used in the first- and second-line settings. Data looking at combinations with ramucirumab are emerging and appear promising, according to Cusnir.

The ramucirumab data can be considered in different patient populations, though the agent appears to have the most activity in patients with borderline poor-performance status, concludes Cusnir.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD